A Case Report on Antibiotics Induced Skin Rashes in a Tertiary Care Hospital in Southern Odisha
DOI:
https://doi.org/10.51168/sjhrafrica.v6i6.1916Keywords:
Antibiotic-induced skin rash, Ceftriaxone, Vancomycin, Adverse Drug Reaction, Pediatric hypersensitivity, PharmacovigilanceAbstract
Background:
Antibiotics, while essential in treating infections, are also among the most common causes of cutaneous adverse drug reactions (ADRs), especially in pediatric populations. This report presents two pediatric cases of antibiotic-induced skin rashes following administration of ceftriaxone and vancomycin.
Case Presentation:
Case 1 involves a 9-month-old male with left-sided empyema who developed erythematous rashes within one hour of receiving intravenous ceftriaxone. The reaction was managed with intramuscular antihistamine (Pheniramine), and ceftriaxone was discontinued.
Case 2 reports a 9-year-old male with pyrexia of unknown origin, who developed widespread rashes after 13 days of vancomycin therapy. The reaction was suspected to be a delayed-type hypersensitivity. Vancomycin was discontinued and intravenous methylprednisolone was initiated.
Causality Assessment:
Both reactions were assessed as “probable” according to the WHO-UMC Causality Assessment Scale.
Discussion:
These cases highlight the potential of beta-lactam (ceftriaxone) and glycopeptide (vancomycin) antibiotics to induce immediate and delayed cutaneous hypersensitivity reactions. While often underreported, these reactions can be managed effectively with prompt drug withdrawal and appropriate treatment. The importance of vigilant pharmacovigilance, especially in pediatric settings, is emphasized.
Conclusion:
Antibiotic-induced skin reactions in children warrant early identification, rational drug use, and avoidance of re-exposure. Strengthening pharmacovigilance practices and conducting larger studies can aid in better understanding and prevention.
Recommendations:
Routine monitoring of pediatric patients on antibiotics for hypersensitivity symptoms, detailed allergy history-taking, timely reporting to pharmacovigilance programs, and patient/caregiver education are essential. Rechallenge with the suspected drug should be avoided.
References
A rare case of Ceftriaxone induced anaphylaxis in anesthesia practice. Anita Kumari1,Ruchi Gupta2,Sukhminder Jit Singh Bajwa2,Jagdeep11 Department of Anesthesiology and Intensive Care, Sri Guru Ramdas Medical College and Hospital, Amritsar, Punjab, India2Department of Anesthesiology and Intensive Care, Gian Sagar Medical College and Hospital, Banur, Punjab, India Year: 2015,Volume : 3,Issue : 1,Page : 106-109
Davey P. Legendre Christina A. Muzny Galien D, et al. Antibiotic Hypersensitivity Reactions and Approaches to Desensitization. Clinical Infectious Diseases, volume 58, Issue 8, 15 April 2014, Pages 1140-1148.
Drug Rashes by Mercedes E. Gonzalez, MD, University of Miami Miller School of Medicine. Last full review/revision Mar 2018. Content last modified May 2025.
International Journal of Science and Healthcare Research Vol.4; Issue 2; April-June 2019 Website: www.ijshr.com Case Report ISSN: 2455-7587 Ceftriaxone Induced Rash Dermatitis: A Case Report Vageeshwari Devuni CMR College of Pharmacy, Kandlakoya, Medchal road, Hyderabad.
Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: An overview. J Postgrad Med. 1996;42:15-22.
Mylan New Zealand Ltd.2011. Vancomycin Data Sheet. 25 May 2011. URL: www.medsafe.govt.nz/profs/datasheet/v/VancomycinMylaninf.pdf (accessed 31 March 2025).
Hospira NZ Limited. 2011 DBL. Vancomycin Hydrochloride Data Sheet. 15 December 2011. URL: www.medsafe.govt.nz/profs/datasheet/v/Vancomycin.pdf (accessed 31 March 2025).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Dr. Suvendu Kumar Panda, Dr. Mousumi Pradhan, Dr. Snehasini Dash, Dr. Jasmine Mahanta
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
